Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Teva to sell...

    Teva to sell contraceptive brand Paragard in 1.1 billion dollar deal

    Written by Ruby Khatun Khatun Published On 2017-09-13T13:43:01+05:30  |  Updated On 18 Aug 2021 3:30 PM IST

    Teva Pharmaceutical Industries, on Monday, agreed to sell its contraceptive brand Paragard to a unit of Cooper Cos for $1.1 billion, on a day the struggling Israeli drugmaker named industry veteran Kare Schultz as CEO.


    The company's U.S.-listed shares were up 1.4 percent at $18.75 in extended trading after closing up 19.3 percent in regular trading.


    The sale of the business is the first step in the planned divestment of non-core assets and the proceeds would be used to repay term loan debt, Teva said.


    Saddled with about $35 billion in debt, Teva has speeded up plans to divest non-core assets, Reuters reported last month, citing sources.


    "Investors will like this news, as in addition to a good price for the asset, and the recent share decline has been likely due in part to investor worries that the debt burden is high," Wells Fargo Securities analyst David Maris said in a note.


    Teva's U.S.-listed stock has halved since early August when it cut its forecasts.


    The company said on Monday it continued to look for divestiture opportunities, including the sale of the remaining assets of its global women's health business, as well as its oncology and pain businesses in Europe.


    Teva said it expects to generate at least $2 billion in total proceeds from the sale of these businesses, as well as additional asset sales to be executed by the end of 2017.


    The deal with Cooper includes Teva's manufacturing facility in Buffalo, NY, which makes Paragard exclusively.


    Paragard, an intrauterine copper contraceptive device, posted revenue of about $168 million for the year ended June 30.


    Teva said it will continue to manufacture and sell Paragard in the United States, until the deal is completed, which is expected before the year end.


    Earlier in the day, Teva named smaller peer Lundbeck's Chief Executive Schultz as its CEO.


    (Reporting by Shailesh Kuber; Editing by Arun Koyyur)

    brandCEOcontraceptiveCooper CosDavid Marisintrauterine copper contraceptive deviceKare SchultzoncologyParagardsellTevaTeva Pharmaceutical
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok